I’ve been thinking about circles.
Not the conceptual kind — though we’ll get there. The physical kind. The ones visible on a map if you trace the journey of a single generic antibiotic from raw chemical to American pharmacy shelf. Start in a chemical plant in Zhejiang province. Ship key starting materials to a synthesis facility in Gujarat. Convert them to an active pharmaceutical ingredient. Ship the API to a formulation plant — maybe still in India, maybe in a bonded zone elsewhere. Tablet, coat, blister-pack, box. Ship the finished dose to a U.S. distribution center. Dispense.
That circle touches three countries, two oceans, and zero domestic manufacturing steps for the active ingredient. For hundreds of medicines Americans take every day, this is not the exception. It is the architecture.
A new assessment from Business Executives for National Security — BENS, the nonpartisan organization that has partnered with senior national security officials since 1982 — maps this architecture with a specificity that should unsettle anyone who has been following the biomanufacturing reindustrialization conversation. Dave Gryska’s team at BENS just released Generic Drug Manufacturing and Biotechnology Innovation — and it does something I’ve been wanting someone outside government to do for years: it treats the generic pharmaceutical supply chain not as a trade policy problem or a healthcare access problem, but as a national security vulnerability with the same structural characteristics as the semiconductor dependency that launched CHIPS.
I’ve written about the biomanufacturing reindustrialization thesis — the circles and spirals, the learning curves, the factory economics, the builder’s playbook. That piece was about the future: the companies and capital structures that could bring biological manufacturing home. This piece is about the present. Because the BENS report reveals that the system we need to reindustrialize isn’t just underbuilt. It is actively structured against its own repair.
The podcast audio was AI-generated using Google’s NotebookLM.
The Numbers Behind the Dependency
Let me put the scale of the problem in terms that are hard to argue with.
Ninety-one percent of drugs prescribed by American physicians are generics. Ninety percent of those generic prescriptions are supplied by India and China. The FDA estimated that approximately 80% of active pharmaceutical ingredients are manufactured overseas. In 2021, 87% of U.S. generic drug manufacturing facilities were located abroad. The United States directly imports roughly 16% of its APIs from China — but India, which supplies the bulk of finished generic doses to American patients, itself imports 80% of its APIs from China.
This is the cascading dependency that the BENS report traces in detail, and it is the feature I want to hold up to the light. Because it’s not a supply chain. It’s a cascade. A disruption in Chinese chemical manufacturing doesn’t just affect Chinese exports. It ripples through India’s pharmaceutical sector and arrives at American pharmacy counters as a shortage — of antibiotics, of cardiovascular drugs, of the basic medications that chronic disease patients depend on to stay alive.
The data on shortages is the trailing indicator. In 2024, the United States recorded its highest number of drug shortages to date — 323 medications affected. Antibiotics have proven especially vulnerable, experiencing shortages at a rate 42% higher than other generics. These aren’t obscure compounds. They’re the medicines that keep a 68-year-old’s blood pressure managed, that treat a child’s ear infection, that a hospital ICU reaches for when a patient goes septic.
And here’s the number that stopped me: the API Innovation Center examined 40 essential drug molecules — the “Vital 40” — and found that India supplies about 63% of these APIs, Europe 22%, China 8%, and the United States just 5%. Five percent. For the most critical generic medicines in the American formulary, domestic production is a rounding error.
But the 8% figure for China is misleading, and the BENS report is careful about why. An analysis of key starting materials (KSMs) — the precursor reagents that are synthesized into APIs — reveals that China is the sole supplier of KSMs for 679 different APIs. India is the sole KSM supplier for 402. The United States and European Union combined are sole suppliers for 44.
Six hundred and seventy-nine to forty-four.
That ratio is the supply chain expressed as a strategic position. And it tells you that the dependency isn’t just about who fills the last step — the tablet press, the blister pack. It’s about who controls the chemistry underneath. China’s dominance isn’t at the visible end of the supply chain. It’s at the foundation. The KSMs are the geology, and everything above them — APIs, formulations, finished doses — is built on ground that someone else owns.
Why the Circle Won’t Break Itself
In the biomanufacturing reindustrialization thesis, I introduced the idea that biomanufacturing fails in circles and scales in spirals. The circle: no production experience means no competitive yields, which means no capital investment, which means no facilities, which means no production experience. The system is closed. Nothing moves.
The generic drug supply chain is this circle in its most advanced failure state. It didn’t get here by accident. It got here by economic logic operating without strategic constraint — and the BENS report traces the history precisely enough that the mechanism becomes clear.
The 2000 elimination of tariffs on formulated pharmaceuticals — following the 1995 WTO Pharmaceutical Tariff Elimination Agreement — incentivized importing finished drug products. Domestic manufacturing became progressively less competitive. Facilities closed. The Viatris plant in West Virginia — once employing 1,400 workers producing critical generic medications across antibiotics, cardiovascular, and autoimmune therapeutic areas — is one example among many. America’s last factory producing penicillin closed in 2004. Not because the science was lost. Because the economics were untenable.
And here is where the circle logic becomes vicious. Once domestic production stops, the workforce disperses. Once the workforce disperses, restarting production requires not just capital but a labor pool that no longer exists. Once facilities close, the institutional knowledge embedded in those facilities — the process optimizations, the supplier relationships, the regulatory compliance infrastructure — evaporates. You cannot restart what you’ve forgotten how to do. Or rather, you can — but at vastly greater cost and time than maintaining it would have required.
This is why I called it a system designed to prevent its own repair. The cost advantage of foreign production compounds over time. Every year of offshoring means another year of learning curve accumulated abroad and lost domestically. China’s 20,000+ chemical companies, accounting for 40% of global chemical industrial output, aren’t just competitors. They’re the installed base. And by some estimates, it costs 50% less to produce APIs in India versus the United States or Europe, with labor costs in India and China estimated at one-tenth the cost for a Western company.
The circle doesn’t just trap individual companies. It traps the entire sector. The margins on generic drugs are already razor-thin — that’s the whole point of generics. Domestic production faces stringent regulatory compliance, higher labor costs, higher energy costs, and competition from established foreign producers who have been descending the learning curve for decades. No individual company can break this circle alone. The economics won’t allow it.
This is where the BENS report’s framing matters: this is a national security problem requiring a national security response. Not because the market failed in some abstract sense, but because the market optimized for exactly the wrong thing — unit cost — while ignoring systemic fragility. And fragility, in a system that 91% of American prescriptions depend on, is an existential risk wearing the mask of efficiency.
Stockpiles Are Sandbags, Not Levees
The BENS report takes SAPIR — the Strategic Active Pharmaceutical Ingredients Reserve — seriously, and I want to amplify the point because it cuts against a comfortable assumption in Washington.
In August 2025, an executive order directed the Administration for Strategic Preparedness and Response (ASPR) to identify and stockpile APIs for approximately 26 essential medicines. SAPIR is being refilled and expanded. This is a good and necessary step. Stockpiling APIs, which have longer shelf lives than finished drug products, reduces risk at multiple stress points in the supply chain.
But the BENS report says what I’ve been arguing in different language: stockpiling alone is insufficient. It is a passive defense mechanism. It buys time. It does not solve the structural deficit. Without a functioning industrial base to replenish the stockpile, the reserve is a finite resource that will run dry in a prolonged crisis.
Think about what that means operationally. A geopolitical disruption — a Taiwan Strait crisis, an escalation in the South China Sea, a deliberate Chinese export restriction on pharmaceutical precursors — doesn’t resolve in weeks. The scenario that matters isn’t a temporary supply interruption. It’s a sustained one. And a stockpile sized for months faces a crisis measured in years.
The analogy I keep returning to: SAPIR is sandbags. Essential during a flood. Useless for preventing the next one. What you need is a levee — domestic production capacity that can sustain the flow regardless of what happens upstream in the geopolitical watershed.
And the geopolitical risk is not theoretical. The BENS report documents that China demonstrated its willingness to use raw materials dominance as strategic leverage when Beijing announced new export controls on rare earths and magnets in October 2025. China’s 2020 Export Control Law and 2021 Biosecurity Law provide extensive powers to weaponize pharmaceutical exports. A 2023 Department of Defense study found that 27% of U.S. military drug purchases depend on PRC suppliers. During COVID, India temporarily banned exports of 26 APIs and pharmaceutical formulations. China’s lockdowns shuttered approximately 37 pharmaceutical factories manufacturing active ingredients for U.S. drug products.
These aren’t hypotheticals. They’re precedents.
Where the Spiral Starts for Generic Drugs
So where does the spiral begin? How do you break a circle this entrenched?
The BENS report’s recommendations align with the NSCEB architecture I’ve written about — and that alignment itself is significant. When a nonpartisan national security organization staffed by senior business executives arrives at the same structural conclusions as the government commission, the signal is strong. Incentivize domestic manufacturing. Enhance supply chain transparency. Advance manufacturing innovation. Strengthen allied partnerships. Expand strategic reserves. Develop the workforce.
But I want to push beyond the recommendation headers — because the generic drug challenge reveals something specific about where the biomanufacturing spiral must enter.
The entry point isn’t biologics. Not yet. The entry point is chemistry.
The KSM dependency — China as sole supplier for 679 APIs’ starting materials — means that reindustrialization for generic drugs starts with chemical synthesis capacity. This is not the glamorous frontier of synthetic biology and AI-driven biodesign that dominates conference panels. It is industrial chemistry. Reactor vessels and distillation columns. Solvent recovery and waste treatment. The unsexy infrastructure that makes everything else possible.
And this is where the advanced manufacturing innovation piece becomes critical — and where I think the conversation needs to get more specific than the recommendation headers usually allow.
The BENS report recommends continuous manufacturing technologies. I want to explain why this isn’t incrementalism. It’s the physics that changes everything.
Traditional batch chemical manufacturing — the dominant mode for API synthesis globally — runs in discrete cycles. Load reagents, react, purify, test, repeat. Each batch is a separate event. Each event requires operators. Each operator costs ten times more in West Virginia than in Gujarat. That math is why the factories left.
Continuous flow chemistry inverts the model. Reagents flow through microreactors or tubular systems without stopping. The reaction happens in transit. Purification is in-line. Quality monitoring is real-time. A continuous process that runs 24 hours produces in a closet-sized reactor what a batch plant produces in a warehouse — with fewer operators, less waste, tighter process control, and yields that improve with runtime because the system is constantly self-correcting.
Here’s the Wright’s Law connection that I think the policy community hasn’t fully internalized: continuous manufacturing doesn’t just reduce labor cost. It steepens the learning curve. In batch manufacturing, each batch is semi-independent. In continuous manufacturing, every hour of runtime generates process data that feeds back into optimization. The learning compounds at the rate of hours, not batches. That’s the difference between a flat curve and one that actually descends fast enough to close the cost gap with foreign producers within a commercially relevant timeframe.
The capital cost is higher upfront. The regulatory validation pathway is less established — FDA has been encouraging continuous manufacturing, but the approval precedents are still accumulating. These are real barriers. But they are surmountable barriers, which is categorically different from the structural barrier of trying to compete on labor cost in batch production. You can solve an engineering and regulatory problem. You cannot solve the fact that your labor costs ten times what your competitor’s does.
The reporting requirements the BENS recommends — mandating that manufacturers disclose the geographic origins of APIs, KSMs, and finished drug products to federal agencies — would create the supply chain map that currently doesn’t exist. And you cannot fix a system you cannot see. The supply chain mapping recommendation — a national database tracking critical nodes, chokepoints, and dependencies — is the diagnostic tool that enables everything else. It transforms supply chain vulnerabilities from unknown risks into managed variables.
The allied sourcing piece connects directly to the friend-shoring thesis I’ll develop further in this series. Canada, the EU, Japan — nations with robust regulatory standards and aligned strategic interests — should be preferred sourcing partners for the supply chain segments that cannot be reshored immediately. Not autarky. Strategic diversification. Building redundancy through allies who share democratic values and regulatory standards, so that no single point of failure — geopolitical, climatic, or logistical — can cascade through to American patients.
What the Generic Drug Supply Chain Teaches Biomanufacturing Builders
Here’s where I want to connect back to the thesis, because the BENS report illuminates something about biomanufacturing reindustrialization that the startup-focused conversation misses.
The generic drug supply chain is the finished product of the circle. It’s what the biomanufacturing ecosystem becomes if the spiral doesn’t start in time. Two decades of rational economic decisions — each one defensible in isolation — producing a system so fragile that a factory fire in Gujarat or an export restriction from Beijing can leave American hospitals rationing antibiotics.
The lesson for biomanufacturing builders is temporal. The window I wrote about in the first installment of this series isn’t just about the learning curve for biologics and engineered organisms. It’s about preventing the generic drug story from repeating in the next generation of medicines. Biosimilars. Cell and gene therapies. mRNA therapeutics. The production platforms of the next two decades are being established right now. Where they’re built, who operates them, and whose supply chains they depend on — those decisions, made in the next five years, will determine whether the next generation of medicines is manufactured in a system that looks like the generic drug cascade or one that looks like a resilient, diversified, domestically anchored spiral.
The BENS report puts data behind what builders already sense: the cost of dependency is not measured in the price of a pill. It is measured in the 323 shortages. In the hospitals that cannot access basic antibiotics. In the military pharmacies that depend on adversarial supply chains for 27% of their purchases. In the cascading fragility that turns a distant factory closure into an American patient’s missed dose.
That’s the cost of the circle.
The engineer I described in the first installment of this series — the one troubleshooting the fermentation run at 5,000 liters — represents the future of biomanufacturing. Skilled, operational, working at the frontier of what domestic production can do.
But there’s another figure in this story who deserves attention. The pharmacist checking inventory and discovering that three generic antibiotics are backordered with no estimated resupply date. The hospital procurement officer calling a second distributor, then a third, then issuing an internal alert about rationing protocols. The patient whose chronic medication — the one that’s kept their condition managed for eight years — is suddenly unavailable.
They don’t stand in a facility that smells like warm yeast. They stand at the endpoint of a supply chain that routes through Zhejiang and Gujarat and arrives — or doesn’t — at an American counter.
The reindustrialization thesis isn’t just about building the future. It’s about repairing the present. And the present is 679 to 44, 323 shortages, and a system where the most powerful nation on Earth cannot reliably produce the basic medicines its citizens take every morning.
The spiral has to start somewhere. The BENS report tells us exactly where.
At the frontier of technology, the experiment is not whether we can engineer the next generation of medicines. It’s whether we can manufacture the current one — here, reliably, without routing our health security through nations that have already demonstrated their willingness to use it as leverage.
The circle is patient. It will wait for us to notice.
— Titus
